Plant ID: NPO20598
Plant Latin Name: Lythrum salicaria
Taxonomy Genus: Lythrum
Taxonomy Family: Lythraceae
NCBI TaxonomyDB:
13129
Plant-of-the-World-Online:
147990-2
Antibiotic; Antidiarrhoeal; Astringent; Hypoglycaemic; Styptic; Vulnerary
Turkey; Italy; Ireland; France; Ethiopia; Peru; Norway; Belarus; Algeria; China; Belgium; Germany; Spain; Ukraine; Netherlands; Denmark; Poland; Finland; United States; Morocco; Sweden; Switzerland; Russia; Bulgaria; Romania; Albania; Portugal; South Africa; Tunisia; United Kingdom; Austria; Greece; Hungary
GPR35; | |
NPSR1; | |
ACHE; | |
RECQL; TDP1; MIF; ALOX12; HSD17B1; HPGD; AKR1B1; HSD17B10; NOX4; ALDH1A1; APEX1; POLB; | |
TEK; INSR; PIM1; MET; AXL; FLT3; CDK1; EGFR; NUAK1; SRC; KDR; IGF1R; AURKB; CSNK2A1; | |
CA12; CA9; CA7; CA4; | |
ESR2; | |
KDM4E; | |
PTGS1; | |
MMP12; | |
HIF1A; | |
FUT7; | |
SLC22A6; | |
SMAD3; LMNA; THPO; HSPA1A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | MIF | Macrophage migration inhibitory factor | P14174 | CHEMBL2085 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0020037; heme binding | 1.071E-09 | 5.828E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4, PTGS1, SRC |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.467E-09 | 7.258E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 4.193E-09 | 1.826E-06 | AXL, EGFR, INSR, MET, NOX4, SRC, TEK, THPO |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.588E-09 | 3.004E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.886E-08 | 1.438E-05 | CA12, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0042562; hormone binding | 7.296E-08 | 1.937E-05 | ACHE, ALDH1A1, EGFR, HSD17B1, IGF1R, INSR |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.206E-07 | 2.950E-05 | EGFR, IGF1R, INSR, KDR, SRC |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.119E-07 | 4.756E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.123E-07 | 6.476E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 3.736E-07 | 7.533E-05 | AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 4.554E-07 | 8.934E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 6.087E-07 | 1.123E-04 | AKR1B1, APEX1, CA9, CSNK2A1, CYP1A2, EGFR, FLT3, HPGD, INSR, SRC, TEK |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 6.167E-07 | 1.128E-04 | EGFR, KDR, MIF, NOX4, SRC, TEK, THPO |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.275E-06 | 2.135E-04 | EGFR, INSR, KDR |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.374E-06 | 2.285E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.028E-06 | 3.244E-04 | CA12, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.063E-06 | 4.632E-04 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 3.817E-06 | 5.579E-04 | CYP1A1, HIF1A, LMNA, NOX4, SMAD3, SRC, TEK |
BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 4.193E-06 | 5.871E-04 | AXL, HIF1A, HSPA1A, MMP12 |
BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 4.329E-06 | 6.004E-04 | CDK1, EGFR, FLT3, INSR, MIF, NOX4, SRC |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.604E-06 | 6.265E-04 | CA12, CA4, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 6.174E-06 | 7.862E-04 | ACHE, AKR1B1, ALDH1A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, EGFR, HSPA1A |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 6.304E-06 | 7.981E-04 | APEX1, POLB |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 7.290E-06 | 8.919E-04 | CA4, CA9, EGFR, HPGD, SLC22A6, TEK |
BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 8.957E-06 | 1.066E-03 | ACHE, AKR1B1, ALOX12, CSNK2A1, CYP19A1, CYP1A1, HSD17B1, MIF, PTGS1 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.133E-05 | 1.299E-03 | CDK1, EGFR, IGF1R, INSR |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.922E-05 | 2.032E-03 | EGFR, IGF1R, INSR, KDR, TEK |
MF | Unclassified; | GO:0032403; protein complex binding | 2.519E-05 | 2.612E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP12, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.622E-05 | 2.693E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 2.747E-05 | 2.769E-03 | ACHE, EGFR, HIF1A, MIF, MMP12, SRC |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 3.470E-05 | 3.343E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.770E-05 | 3.523E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.770E-05 | 3.523E-03 | CYP1A2, CYP2C9 |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 4.337E-05 | 3.887E-03 | ALOX12, CYP1B1, HIF1A, KDR, TEK |
BP | GO:0040007; growth | GO:0045927; positive regulation of growth | 4.338E-05 | 3.887E-03 | ALOX12, CDK1, CSNK2A1, EGFR, INSR, PIM1 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 5.351E-05 | 4.614E-03 | AXL, IGF1R, INSR |
BP | GO:0032501; multicellular organismal process | GO:0001819; positive regulation of cytokine production | 5.809E-05 | 4.903E-03 | CYP1B1, HIF1A, HSPA1A, MIF, MMP12, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 5.935E-05 | 4.971E-03 | FLT3, SRC, TEK |
BP | Unclassified; | GO:0006461; protein complex assembly | 7.229E-05 | 5.783E-03 | ACHE, CDK1, HSD17B10, HSPA1A, IGF1R, INSR, MIF, SLC22A6, SMAD3, SRC, TEK |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 7.225E-05 | 5.783E-03 | CSNK2A1, HIF1A, KDR |
BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 7.578E-05 | 5.999E-03 | CA9, EGFR, HIF1A, MET, SMAD3, SRC |
BP | GO:0008283; cell proliferation | GO:0050679; positive regulation of epithelial cell proliferation | 7.961E-05 | 6.125E-03 | EGFR, HIF1A, KDR, MMP12, TEK |
BP | GO:0008152; metabolic process | GO:1903580; positive regulation of ATP metabolic process | 8.686E-05 | 6.590E-03 | CDK1, HIF1A, INSR |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 8.686E-05 | 6.590E-03 | CYP19A1, CYP1A1, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 8.857E-05 | 6.697E-03 | ACHE, CDK1, CYP1A1, EGFR, SMAD3 |
BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 9.395E-05 | 6.958E-03 | ALOX12, HPGD |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.395E-05 | 6.958E-03 | CYP1A2, CYP2C9 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 9.355E-05 | 6.958E-03 | EGFR, INSR, KDR, SLC22A6, SRC, TEK |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 9.819E-05 | 7.174E-03 | HIF1A, HSPA1A, MIF, SRC |
BP | GO:0008152; metabolic process | GO:0016101; diterpenoid metabolic process | 1.065E-04 | 7.702E-03 | ALDH1A1, CYP1A1, CYP1B1, EGFR |
BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.313E-04 | 9.088E-03 | EGFR, POLB |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.313E-04 | 9.088E-03 | FLT3, KDR |
MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 1.315E-04 | 9.088E-03 | CYP1A1, CYP1A2, KDM4E |
BP | GO:0009987; cellular process | GO:0051495; positive regulation of cytoskeleton organization | 1.324E-04 | 9.127E-03 | HSPA1A, MET, NOX4, SMAD3, TEK |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 5.386E-10 | 6.679E-08 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.307E-09 | 1.430E-07 | HSD17B1, INSR, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 7.768E-07 | 1.926E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.974E-07 | 9.221E-06 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 3.042E-06 | 6.286E-05 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.391E-08 | 3.055E-06 | CA12, CA4, CA7, CA9 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.873E-06 | 1.530E-04 | SRC, KDR, HIF1A, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 5.232E-06 | 9.269E-05 | INSR, TEK, HIF1A, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.861E-05 | 2.391E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.175E-05 | 2.452E-04 | FLT3, MET, HIF1A, EGFR |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.929E-05 | 2.391E-04 | CYP2C9, CYP1A2, ALDH1A1, CYP1A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.056E-05 | 3.158E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.009E-04 | 8.934E-04 | SRC, EGFR, ESR2, HSPA1A |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.621E-04 | 1.182E-03 | CYP2C9, FUT7, HSD17B1, CYP1A2, ALDH1A1, CYP1A1, AKR1B1, ALOX12, CYP19A1, HSD17B10, PTGS1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.772E-04 | 1.221E-03 | INSR, KDR, TEK, MET, EGFR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.329E-04 | 1.030E-03 | SRC, KDR, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.832E-05 | 4.609E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 4.004E-04 | 2.483E-03 | SMAD3, FLT3, HIF1A, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.141E-04 | 2.050E-03 | SMAD3, INSR, EGFR, IGF1R |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.281E-04 | 1.030E-03 | CYP1A2, CYP1A1, CYP1B1 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 4.658E-04 | 2.661E-03 | THPO, FLT3, KDR, MET, EGFR |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 5.184E-04 | 2.795E-03 | INSR, HSPA1A, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 4.722E-04 | 2.661E-03 | CYP2C9, ALOX12, PTGS1 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 7.026E-04 | 3.485E-03 | MET, EGFR, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 6.192E-04 | 3.199E-03 | SRC, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 9.802E-04 | 4.675E-03 | HPGD, FLT3, MET, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.310E-03 | 6.017E-03 | SRC, CDK1, EGFR |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; PTGS1; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
NA: NA | Miosis during ocular surgery | NA | PTGS1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
NA: NA | Rheumatold arthritis | NA | PTGS1; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; TEK; EGFR; SRC; CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; PTGS1; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | MIF; INSR; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Refractory autoimmune diseases | D84.9, M35.9 | MIF; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; INSR; EGFR; CA9; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; INSR; EGFR; CYP19A1; CA9; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; HIF1A; TEK; EGFR; SRC; CA9; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; MIF; PTGS1; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1; AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |